Genmab A/S (NASDAQ:GMAB) Hits New 1-Year Low – Should You Sell?

Genmab A/S (NASDAQ:GMAB)’s stock price hit a new 52-week low during trading on Thursday . The stock traded as low as $22.26 and last traded at $22.26, with a volume of 35086 shares changing hands. The stock had previously closed at $22.57.

Wall Street Analyst Weigh In

GMAB has been the topic of several analyst reports. Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. Redburn Atlantic began coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Finally, Truist Financial decreased their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

The stock’s fifty day simple moving average is $25.07 and its 200-day simple moving average is $26.69. The firm has a market cap of $14.76 billion, a PE ratio of 18.65, a PEG ratio of 0.68 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. Analysts expect that Genmab A/S will post 1.29 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Capital International Investors increased its stake in shares of Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after acquiring an additional 315,355 shares during the period. Renaissance Technologies LLC increased its stake in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares during the period. DDD Partners LLC acquired a new stake in shares of Genmab A/S in the second quarter worth $8,860,000. Cubist Systematic Strategies LLC increased its stake in shares of Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after acquiring an additional 145,689 shares during the period. Finally, Ingalls & Snyder LLC increased its stake in shares of Genmab A/S by 29.3% in the second quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock worth $5,772,000 after acquiring an additional 52,117 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.